Researchers design one-step procedure for improving effective of adoptive cell immunotherapy against solid tumors ScienceAdvances cellimmunotherapy immunotherapy tumors adoptive
By Neha MathurAug 14 2023Reviewed by Lily Ramsey, LLM In a recent article published in the Science Advances Journal, researchers developed a one-step method to engineer multifunctional M1 phenotype macrophages from specialized membrane-fusogenic liposomes for effective adoptive cell therapy against solid tumors.
Background ACT is a well-recognized cancer treatment involving ex vivo engineering of immune effector cells, including natural killer cells, T-cells, macrophages, etc., and their reinfusion to identify and eliminate tumor cells. An unmet need exists for enhanced ACT against tumors using refined synchronous cell engineering of multiple targets at varying subcellular levels within a single process.
Next, the team evaluated the phagocytosis ability of engineered ARMFUL/M1 macrophages using fluorescence-activated cell sorting . According to the authors, the study developed a membrane fusion–mediated cell engineering technique, which is the first to utilize the membrane fusion effect for cell engineering to construct multifunctional effector cells.